Development of quality indicators for hypertension management at the primary health care level in South Africa

Introduction

South Africa has implemented multiple initiatives to improve the quality of the management of non-communicable diseases (NCDs), specifically hypertension and type 2 diabetes mellitus [1], at the primary health care (PHC) level covering approximately 80% of the population [2]. Consequently, compliance with the provision in the Constitution of the country [3]. This includes a National Strategic Plan for the Management of Non-Communicable Diseases, 2022-2027 [1]. Alongside this, policy and guidelines on monitoring and enforcing adherence to medicines for chronic use in all health facilities have been introduced [4]. In 2021, a National User Guide on the Prevention and Treatment of Hypertension in Adults at PHCs was rolled out. This included interventions to strengthen the monitoring and management of patients with hypertension in the country [5]. Recently, the National Health Insurance Bill paved the way to universal health coverage for all citizens in South Africa [6, 7]. Such interventions are important due to rising rates of NCDs in South Africa as well as an increase in the number of patients with co-morbidities, including both infectious diseases and NCDs [8, 9].

What remains unknown is the quality of care that patients with hypertension are currently receiving at the PHC level in South Africa [1, 10, 11]. It has been suggested that patients with diagnosed hypertension are not receiving recommended care and are often not at target treatment goals. This is exacerbated by possible suboptimal quality of healthcare services at the PHC level [8] and often unavailable antihypertensive medicines within PHC facilities [12]. However, there are not enough reliable data available on the quality of care that patients with hypertension receive at the PHC level in South Africa. As a result, the quality of care currently provided cannot be fully assessed to guide the implementation of policy initiatives for quality improvement [13]. Poor quality of care, coupled with a lack of data to improve care, contribute to avoidable high morbidity and mortality due to hypertension [14]. A summary of what is already known about hypertension management in the public PHC level in South Africa, and the gaps in knowledge this study addresses is presented in the discussion.

Quality indicators measure whether the evidence-based guidelines regarding the current management of hypertension are being implemented [13] and can provide data to monitor the achievement of programme outcomes [15,16,17]. However, currently in South Africa there is no agreed minimum set of indicators to assess the quality of care and to monitor progress towards attainment of the hypertension objectives set out in these initiatives [15]. Developing and testing quality indicators as part of a multiple approach is key to strengthening health programmes and enhancing the quality and efficiency of clinical services [11, 18, 19]. This has implications not only for the management of hypertension in South Africa but also across Africa, given current concerns [20]. Consequently, the aim of this study was to develop evidence-based quality indicators for hypertension management and monitoring at the PHC level for South Africa.

Materials and method

This study used a modified RAND/UCLA Appropriateness Method (RAM), initially developed by RAND Heath staff in collaboration with clinicians at the University of California in Los Angeles (UCLA) [21]. The RAM is an internationally recognized formal group consensus modified Delphi technique that allows for the development of consensus among experts where no previous consensus exists, with individual opinions forming a refined, aggregated and group opinion. This methodology has been used extensively, for example, in the UK for the construction of a patient safety toolkit for general medical practice [22]. It uses a series of sequential steps involving evidence synthesis, clinical scenario or indicator development, panellist selection, two-round rating process and the analysis of the results.

Synthesis of possible quality indicators

The authors, co-ordinated by the lead author (EMR), conducted a rapid evidence assessment to review the international evidence-based clinical guidelines as well as national action plans for the management of chronic NCDs, specifically hypertension. Whilst more than five hypertension guidelines were  identified in the review, only five principal ones were referenced for the purpose of this article to provide a robust and succinct baseline. The purpose was to identify, synthesise and develop quality indicator statements from international and national evidence-based guidelines for the management of diagnosed hypertension in adult patients. The indicator statements were identified and categorised into different dimensions of the quality of care from the quality standards guidelines for the management of hypertension at the PHC level, sourced from international and national guidelines and the National Strategic Plan for Non-communicable Diseases in South Africa (see Table 1) [1, 5, 23,24,25].

Table 1 Key sources of quality indicator statements.
Full size table

RAND/UCLA Appropriateness Method (RAM)

The RAM was used to identify the clarity, appropriateness and feasibility of the quality indicator statements that were derived from the literature review as part of an ongoing indicator development and testing protocol [26]. Panellists for the RAM were selected to create a multidisciplinary panel that reflected the range of health care professionals (HCPs) currently involved in the day-to-day management of people with diagnosed hypertension in South Africa. In addition, to contain a mixture of international/national experts along with other HCPs working in PHC facilities in South Africa. Panellists were recruited using nominations from professional associations, national, provincial and districts health departments and institutions of higher learning, including tertiary hospitals.

All panellists were involved in both rounds of the RAM. Panellists were sent a copy of the synthesised evidence synthesis, an instruction sheet including definitions of terms and the rating scale before completing the two appropriateness rating rounds. In both rounds, the panellists had the same number of hypertension quality indicator statements, grouped within 9 dimensions for their consideration and rating, based on the different sections of hypertension management guidelines nationally and internationally [1, 5, 23,24,25]. The dimensions consisted of “monitor, review, lifestyle advice, blood pressure levels, treatment, tests, intermediate outcomes, referrals and practice/facility” quality indicator statements. These dimensions are aligned to the sub-sections of the hypertension guidelines, for example, the section on treatment and monitoring of hypertension management as well as referral of patients within different levels of care.

In applying the rating scale, panellists were instructed to consider an adult patient (≥18 years) with a confirmed diagnosis of hypertension being managed by an ‘average clinician under average circumstances in the PHC setting in South Africa’.

Definitions used for clarity, appropriateness and feasibility in the context of this study were as follows:

Clarity meant that the indicator wording is clear and precise with unambiguous language [26]. Appropriate was defined as whether something would be an appropriate next step clinically for the ‘average’ patient in the ‘average’ PHC/ambulatory setting, seeing the ‘average’ HCP in South Africa with a rating of 7-8 [24, 26]. Necessary care was defined as an appropriate next step, without exceptions. Feasibility was defined as whether something would be feasible to implement, and data would be available for the ‘average’ patient in the ‘average’ PHC/ambulatory setting seeing the ‘average’ HCP, in terms of human resources, financial and other restraints in the context of South Africa [24, 26].

This study used the RAM which promotes robust, credible, and valid hypertension quality indicators, as this methodology combines the available scientific evidence and expert opinion in the management of hypertension [27, 28]. It is a practical, real-world method, designed to identify appropriate clinical steps tailored to patient needs and grounded in everyday practice of practitioners and facilities [21]. Unlike other consensus techniques such as the Delphi Technique, the RAM incorporates interactive discussion of indicator statements between panellists in Round 2. Online RAM panel meetings have been used successfully, in part in response to restrictions imposed by the COVID-19 pandemic, with online meetings at a reduced cost [28].

Consensus procedure

The RAM was completed in two rounds. The first round consisted of an online MS Excel® rating spreadsheet that was sent to the panellists by email. The email requested them to rate the list of hypertension quality indicator statements on a 9-point integer scale, separately for clarity and appropriateness. Panellists were invited to provide alternative wording for the indicators or suggest new indicators if wished. The second round was an online face-to-face MS Teams® meeting chaired by two chairpersons: a clinical chairperson (NNN) and the methodologist chairperson (SMC) with experience in the use of consensus methods in different settings [27].

An MS Excel® spreadsheet was used to collate data from the completed first-round rating sheets with the median rating for each indicator calculated for clarity and for appropriateness. The frequency distribution of each response on the 1–9 scale for each indicator for clarity and appropriateness was calculated.

For Round 2, first-round data were used to create personalised rating sheets for each panellist showing the median for each indicator for clarity and appropriateness and the frequency distribution of all panel ratings across the 9-point integer scale for each indicator. This enables each panellist to see the first-round ratings of appropriateness from the full panel (confidentially to each panellist) and a reminder of how they rated each indicator in Round 1. Five days prior to the online meeting, panellists were sent their personalised rating sheet, an instruction sheet, source of evidence for the quality indicator statements, a summary of Round 1 and an introduction presentation explaining the RAM and purpose of Round 2. With agreement from all panellists, the panel was sent a short biography of each panellist.

The two chairs (SMC and NNN) of the second-round face-to-face online meeting also received an MS Excel® rating spreadsheet, showing how each panellist had rated each indicator in Round 1. In Round 2, panellists rated the indicators for appropriateness again and for feasibility in terms of the PHC level settings in South Africa using a 9-point scale for appropriateness and feasibility (See Table 2 for an explanation of the 9-point rating scale and panel rating scale consensus).

Table 2 9-Point rating scale for appropriateness and feasibility.
Full size table

An MS Excel® spreadsheet was used to collate data from the completed second-round rating sheets with the median rating for each indicator calculated for appropriateness and for feasibility. The frequency distribution of each response on the 1–9 scale for each indicator was calculated for appropriateness and feasibility.

Data analysis

In both rounds of the RAM, the level of agreement for each indicator was calculated according to the conventional RAM method of percentage of ratings within the same tertile as the median (<25% as ’agreement’; ≥33% in both 1–3 and 7–9 ranges as ’disagreement’; all indicators without consensus [either agreement or disagreement] as ’equivocal’)’ [21, 29].

All data analyses and findings are based on Round 2 of the RAM.

Results

Panel composition

The panel was composed of 11 members in Round 1 of the RAM. Round 2 was composed of 10 members although one panellist failed to submit their rating scores resulting in a panel of 9 members. These included four family physicians, one cardiologist, one pharmacist, two clinical pharmacists and one clinical nurse practitioner. All panellists were involved in the management of hypertension patients and  contributing to development and review of hypertension guidelines, either at an international, national, provincial or district level.

Quality indicator statements

There were 102 quality indicator statements listed and grouped under the 9 different domains of quality of care on the MS Excel® rating spreadsheet. No panellist provided alternative wordings for the indicators or suggested new indicators. The full list containing all 102 statements is available on request from the authors.

Table 3 summarises the results of the Round 2 indicator ratings with 46 quality indicator statements for hypertension (45.1%) rated appropriate (overall panel rating 7-8-9) and feasible (overall panel rating 7–9). None (0%) were rated with disagreement and 46 (45.1%) were rated equivocal for either or both scales. Of the 46 indicators rated appropriate, 10 (9.8%) were rated as a necessary next step without exceptions. For all indicators on both scales, there was agreement that no action was inappropriate (overall panel rating 1-2-3).

Table 3 Summary of appropriate and feasible ratings for round 2 RAM.
Full size table

Only statements rated ≥7 with agreement were considered appropriate or feasible (Table 3). Under appropriateness, there were two statements rated 6 with agreement, and one statement rated 5 with agreement. Under feasibility, there were 9 statements rated 6 with agreement. There were 7 and 42 statements rated equivocal under appropriateness and feasibility respectively.

Table 4 shows the list of 46 statements for which the panel reached consensus in terms of their appropriateness and feasibility for hypertension management at the PHC level. Panellists did not find a single indicator being appropriate and feasible for the dimensions ‘patient blood pressure and patient treatment’. All the indicators about ‘advice about lifestyle and intermediate outcome’ were rated as appropriate and feasible. Most of the indicators under the dimensions ‘monitoring’ and ‘review of patients’ and indicators under the dimension ‘tests’ were found appropriate and feasible.

Table 4 List of hypertension management indicators rated appropriate and feasible.
Full size table

Patient blood pressure level

All four quality indicators which categorised blood pressure levels as normal, mild, moderate, and severe hypertension were rated appropriate; however, three were not seen as feasible and one as equivocal. An example of these indicators is ‘The % of patients in the practice/unit/facility who has blood pressure ≤140/90 mmHg’, which is seen as equivocal. The three indicator statements about the percentage of patients in the facility that have mild, moderate, and severe hypertension were though not rated as feasible.

Patient treatment

Most of the 17 indicator statements about the percentage of patients in different steps of the stepwise treatment without compelling indications, or with a specific condition such as stroke in the last 3 months, were rated appropriate, but in all the statements their feasibility was seen as equivocal. An example of these indicators is ‘The % of patients in the practice/unit/facility who are on the treatment of hypertension with angina in the last 3 months’.

Discussion

The WHO, World Bank Group and Organisation for Economic Co-operation and Development have identified the five foundational elements critical to delivering quality health care services as being health care workers; health care facilities; medicines, devices, and other technologies; information systems; and financing [15]. It is imperative to develop and apply a tested hypertension management framework that is congruent to these foundational elements in South Africa as well as Africa as a whole, to enhance the potential utility of applying agreed indicators.

Substandard quality of care contributes to the global disease burden and unmet health needs in the population [1, 15]. The lack of data regarding the quality of care provided to patients with hypertension at the PHC level in South Africa is associated with the lack of processes and tools to measure the quality of care [30]. This is because sustained quality improvement within the current public health care system, and the provision of appropriate care, remains problematic in South Africa [13]. Consequently, it is important for the Ministry of Health in South Africa to strengthen existing quality improvement initiatives to reduce the rising burden of NCDs in the country.

Hypertension currently exerts a considerable health and economic burden on South Africa [13], with evidence that patients are currently not receiving the necessary evidence-based care in PHC facilities [5, 12]. The focus on monitoring patients with hypertension in South Africa is an imperative given the low levels of reported medication adherence [31], and the fact that one‑third of patients often do not receive all their antihypertensive medicines from PHC facilities due to supply chain issues and generally poor access to quality care [7, 12]. This is also important for achieving the aim of Universal Health Coverage and to reduce high morbidity and mortality due to hypertension in South Africa, which is a key target for the National Strategic Plan for NCDs [13].

We believe this is the first time quality indicators have been developed for use in primary care in South Africa, based on hypertension management guidelines. A multidisciplinary panel of experts, all involved in the day-to-day management of people with hypertension, and from different provinces of South Africa, were used in the development of possible indicators. The mixed sample of panellists resulted in a wide variation of relevant views to hypertension management, including authors’ of the South African Hypertension Guidelines, to enhance the possible utility of considered indicators.

From 102 guideline-based quality indicators, 45.1% of the quality indicators were rated both appropriate and feasible with agreement to improve the management of patients with diagnosed hypertension at the PHC level in South Africa. The individual-level indicators are intended to build the data for the whole practice indicators. The number of patients in which the individual-level indicator was applied becomes the numerator for the practice indicators, whereas the total number of patients who were managed in the facility would become the denominator for the practice indicators.

Lifestyle and behavioural changes can lead to improved hypertension outcomes in mild hypertension without the need for antihypertensive treatment [32]. Even in resistant hypertension, it is important to maintain advice on a healthy lifestyle during drug therapy [32]. Lifestyle advice is also important as previous research reported that 16.6% of people with hypertension indicated that financial difficulties were the cause of challenges in accessing medicines [33]. This is particularly the case in low- and middle-income countries with high levels of patient co-payments where illness can have catastrophic consequences for families.

Monitoring intermediate outcomes in the management of hypertension is an important intervention in improving the quality of care and patient outcomes [11, 18, 19, 34]. They assist with increasing the number of patients who are at the treatment goal of a blood pressure <140/90 mmHg and with identifying those currently not yet at their treatment goal as well as informing future interventions [8].

Whilst the panel agreed that all the indicators under the dimension ‘blood pressure levels’ were appropriate, they also agreed that it was not feasible to determine the number or percentage of all patients with blood pressure above the target goal (≥140/90 mmHg) in the context of PHC in South Africa. Panellists were also equivocal on one of the indicators under this dimension, which was about determining the number or percentage of patients with controlled blood pressure (<140/90 mmHg). The decisions of the panellists on the indicators under the dimension of ‘blood pressure levels’ can be considered appropriate, considering that the panellists found all the indicators in the dimension of ‘intermediate outcome’ as appropriate and feasible.

All the indicators under the dimension ‘intermediate outcome’ concern the number or percentage of patients with a blood pressure of <140/90 mmHg with no adverse reactions in patients who are already on hypertension medication in different steps of the algorithm of hypertension management. The data on the indicators under the dimension ‘intermediate outcome’ can indirectly lead to the number of patients who are not at treatment target goals (blood pressure level). Consequently, the agreement of the panellists that the use of the indicators under the ‘blood pressure level’ is not feasible. Their decision may also have been based on the evidence that measuring quality requires measuring positive outcomes, count, or percentage of patients with a blood pressure of <140/90 mmHg in this case, and not vice versa [8].

The panel also found most of the indicators under the dimension ‘treatment’ and ‘blood pressure level’ appropriate but either with equivocal feasibility or not feasible. The main reason for the panellists not finding the indicators under the dimensions ‘treatment’ and ‘blood pressure level’ feasible was a concern about the data quality and precision needed in the recording of data, as data management is currently mostly manually and only partially electronic. The panellists also emphasised the need to use quality indicators as a means to assess the management of patients with hypertension, in the context of the RAND/UCLA Appropriateness Method focus on the ‘average’ patient, not those with specific details. Further work will be required to modify the indicators especially those encompassing adherence to the stepwise approach to the management of hypertension (indicators under ‘treatment’ dimension). Indicators rated appropriate and feasible under the dimension ‘referral’ may assist in identifying the data for which indicators under the dimensions ‘blood pressure levels’ and ‘treatment’ were intended for. Based on the assumption that guidelines in the management of hypertension at the PHC level are adhered to, the indicators under the dimension ‘referrals’ would provide the measure in which the indicators under ‘blood pressure level’ and ‘treatment’ dimensions were intended for.

Most of the indicators under the dimensions ‘monitoring’ and ‘review of patients’ were found appropriate and feasible. These indicators underpin the importance of recording activities and measurements that should be undertaken with the patient during the visit. Subsequently, provide the basis for quality of health care actions to be addressed in other dimensions. This is also important as it facilitates population level data collection with accurate data, which can then be used to inform future interventions needed to improve and sustain the quality of care at the PHC level in South Africa.

Most of the indicators under the dimension ‘tests’ were also found to be appropriate and feasible. This is imperative as these indicators are about recording the tests that are performed with patients.

Conclusions and implications for patient care

Applying the care stated in these indicators would improve clinical outcomes and the quality of life for patients with a confirmed diagnosis of hypertension being treated at the PHC level in South Africa. As a result, help reduce avoidable harm, morbidity and mortality. In addition, contribute towards more effective and efficient use of scarce health care resources.

Consequently, our findings have implications not only for key stakeholder groups in South Africa to improve the care of patients with hypertension in the public system, but also across Africa.

Hypertension is the leading modifiable cardiovascular disease risk factor in South Africa. This study provides a possible solution to the current lack of quality measuring tools of health care provided to patients with hypertension at the PHC level through identifying 46 evidence-based quality indicators specifically tailor-made to suit South African public PHC level settings. The indicators and framework for hypertension management from this study can be replicated for the management of type 2 diabetes mellitus and other NCDs in South Africa, which is a priority of the National Department of Health [1].

Outcomes from consensus techniques have face or content validity but the next step of the ongoing indicator development and testing protocol will be to test the 46 developed hypertension quality indicators for their data feasibility, reliability, and validity. In addition, to determine what implementation strategies might be needed in terms of workforce, facilities and medicines supply to be able to apply the indicators at the PHC level in South Africa. Testing will also consider the clinimetric properties of the indicators to assess their value as precise measurement instruments and proxy indicators for quality assessment including the availability of routine data, variability, measurability, applicability and potential room for improvement [35] in addition to assessing the appropriateness of hypertension management in the context of routine PHC/ambulatory care practice in South Africa. The implementation strategies and the definition of these indicators would be clearly articulated based on the South African PHC settings in a follow-up publication after testing the indicators at the PHC level. Reliable information is the foundation of decision-making in health care and appropriate next clinical steps for people with confirmed NCDs [16].

Summary

What is known about quality of care for patients with hypertension

  • Evidence-based guidelines for the management of hypertension are available [1, 4, 5, 23].

  • No locally agreed indicators to measure the quality of care in the management of hypertension at the PHC level in South Africa [15].

  • There are concerns with the quality of care and control of blood pressure amongst patients diagnosed with and managed for hypertension at the PHC level in South Africa [8, 13].

What this study adds in the quality of care for patients with hypertension

  • Provide appropriate and feasible quality indicators that can be tested for implementation to measure and track quality of care for hypertension at the PHC level.

  • Lay foundation for future development of appropriate and feasible quality indicators for the management of other non-communicable diseases in Africa.

  • Provide all stakeholders with a platform to agree on suitable measures of quality of care, making it easy for acceptability and implementation.

Related Articles

Exploring corporate social responsibility practices in the telecommunications, broadcasting and courier sectors: a comparative industry analysis

This study aims to dissect and understand the Corporate Social Responsibility (CSR) endeavours of organisations within Malaysia’s telecommunications, broadcasting, postal and courier services sectors, particularly those holding licenses from the Malaysian Communications and Multimedia Commission (MCMC). These sectors were chosen for this study due to their crucial role in Malaysia’s economy and society, their notable environmental influence, the regulatory and public attention they receive as well as the distinct challenges and opportunities they face in implementing CSR. Employing a qualitative methodology, the study utilises a semi-structured interview protocol to gather rich, detailed insights from top management across eight listed and non-listed companies. This approach ensures a comprehensive exploration of CSR types, practices and their implementation within the target sectors. Purposive sampling was adopted to select informants with specific expertise, ensuring that the data collected was relevant and insightful. The findings of this study underscore that while telecommunications firms actively participate in Corporate Social Responsibility (CSR) initiatives, their efforts predominantly benefit the broader society, with less emphasis placed on shareholders. Additionally, it was observed that environmental issues receive relatively minimal attention from these organisations. This diversity highlights the necessity for a more equitable CSR approach that caters equally to the needs of all stakeholders, including the environment. Such a strategy is crucial for cultivating a sustainable and ethically sound business environment. The implications of this research are manifold. For companies, it emphasises the critical nature of adopting an all-encompassing CSR strategy that fosters competitive advantage while promoting sustainable development. The study advocates for a paradigm shift towards CSR practices that are not only philanthropic but also prioritise environmental stewardship and value creation.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Optofluidic paper-based analytical device for discriminative detection of organic substances via digital color coding

Developing a portable yet affordable method for the discrimination of chemical substances with good sensitivity and selectivity is essential for on-site visual detection of unknown substances. Herein, we propose an optofluidic paper-based analytical device (PAD) that consists of a macromolecule-driven flow (MDF) gate and photonic crystal (PhC) coding units, enabling portable and scalable detection and discrimination of various organic chemical, mimicking the olfactory system. The MDF gate is designed for precise flow control of liquid analytes, which depends on intermolecular interactions between the polymer at the MDF gate and the liquid analytes. Subsequently, the PhC coding unit allows for visualizing the result obtained from the MDF gate and generating differential optical patterns. We fabricate an optofluidic PAD by integrating two coding units into a three-dimensional (3D) microfluidic paper within a 3D-printed cartridge. The optofluidic PADs clearly distinguish 11 organic chemicals with digital readout of pattern recognition from colorimetric signals. We believe that our optofluidic coding strategy mimicking the olfactory system opens up a wide range of potential applications in colorimetric monitoring of chemicals observed in environment.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Responses

Your email address will not be published. Required fields are marked *